fb-pixel Skip to main content
Mass. Movers

Ariad jumps on European drug action

Harvey J. Berger is the CEO of Ariad Pharmaceuticals.
Harvey J. Berger is the CEO of Ariad Pharmaceuticals.Barry Chin/Globe Staff

Shares of Cambridge biotech Ariad Pharmaceuticals surged after European regulators recommended the continued use of its leukemia drug. The Committee for Human Medicinal Products of the European Medicines Agency will continue to allow sales of Iclusig, despite the fact that sales were halted in the United States due to higher-than-expected incidence of blood clotting. Iclusig is approved in both regions for treatment of advanced chronic myeloid leukemia that has shown resistance to other medications.